| Document Date: 2010-02-16 13:48:13
Open Document File Size: 255,17 KBShare Result on Facebook
Company Amgen Inc / Three-Times Weekly / / Country United States / / Event FDA Phase / / Holiday between day / / IndustryTerm alfa / Treatment of Anemia in Cancer / therapeutic biologic products / Treatment of Anemia of Chronic Renal Failure / energy / / MedicalCondition cervical cancers / tumor / iron deficiency / anemic cancer / congestive heart failure / deep venous thromboses / Cancer / hemodialysis vascular access thrombosis / disease / Uncontrolled hypertension / chronic renal failure / non-fatal myocardial infarctions / deep venous thrombosis / Chronic / neutropenia / ischemic heart disease / stroke / vascular access thromboses / erythropoietin deficiency / severe anemia / fatigue / myocardial infarction / deep vein thrombosis / AIDS / hypersensitivity / solid cancers / renal failure / end-stage renal disease / intercurrent infectious/inflammatory / renal dysfunction / INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE Renal failure / breast cancer / anemia / symptomatic anemia / / MedicalTreatment peritoneal dialysis / antineoplastic therapy / red blood cell transfusion / hip surgery / orthopedic procedures / hemodialysis / concomitant therapy / chemotherapy / radiotherapy / knee surgery / kidney transplantation / Surgery / dialysis / spinal surgery / blood transfusions / / Organization DOSAGE AND ADMINISTRATION / FDA / BOXED WARNINGS and DOSAGE AND ADMINISTRATION / / Position Major / / Product Zidovudine / FOR INJECTION / cisplatin / sodium chloride / SC injection / AUC0-168h / PROCRIT® / / ProvinceOrState South Carolina / / Technology Pharmacokinetics / chemotherapy / ESA / transplantation / recombinant DNA technology / dialysis / /
SocialTag |
FDA Approved: [removed]PROCRIT® (Epoetin alfa) FOR INJECTION WARNINGS: INCREASED MORTALITY, SERIOUS CARDIOVASCULAR and THROMBOEMBOLIC